yarthralgia, vascular thrombosis, consumption of alcoholic beverages, and cigarette or illicit drug use was denied. Previous annual health examinations were normal for 10 years.
On the morning of August 20, 1997, he began to clean the chemical debris since 9:00 AM. However, he felt a floating sensation, chest heaviness, neck tightness, and asthenia 1 hour later. He sat down for rest but whorling, cold perspiration, right facial numbness, unsteadiness on standing, and vomiting subsequently developed. He was first sent to a local hospital, where hematology, biochemistry, and electrocardiogram studies were normal. Then, he was transferred to our emergent service. He and his colleagues denied any powerful smell inside the chamber.
On admission, his blood pressure was 125/70 mmHg, pulse rate 73 beats/min, respiratory rate 17 breaths/min and body temperature 36.7°C. He was conscious, cooperative, and oriented. He complained of severe internal whorling. Neurologic examination revealed truncal ataxia, facial hypesthesia to pinprick pain and fine touch, ptosis, anhydriosis, and miosis at right side. A posterior fossa lesion was considered. Head magnetic resonance imaging showed multiple high T2-weighted lesions compatible with infarct at the right medial cerebellum, right dorsolateral medulla, and left medial cerebellum (Fig. 1) . The magnetic resonance arteriogram and venogram, 24-hour Holter analyzer, cardiac echogram, cerebral angiogram and aortogram, stroke risk factor survey (5,6), hematology, rheology, biochemistry, serology, immunology, toxicology, and trace element studies were normal, except for a 1.6-fold prolongation of activated partial thromboplastin time (aPTT), an increase of blood β 2 GPI-aCL-IgG to 16.5 GPL/mL (normal: <10 GPL/ml), and β 2 GPI-aCL-IgM to 8.8 U/mL (normal: < 6 U/mL). The eosinophil count; IgE; anti-β 2 -glycoprotein I antibody; lupus anticoagulant inhibitor; antimitochondrial antibody; indirect and direct Coombs' test; antinuclear factor; anti-ENA; protein S; protein C; cryoglobulin; clotting factors II, V, IX, and X activity; antithrombin III; antiplasmin; total T cells; active T cells; total B cells; CD4 and CD8 were within reference range. The major histocompatibility complex antigen was A2, A11, B60, Cw10, DR4, and DR17.
Coumadin 2.5 mg/day and acetylsalicylate 100 mg/day were prescribed for prophylaxis. Residual ataxia persisted at discharge. He did not engage the Furax process afterward. On a followup of 80 months until now, his aCL-IgG and aPTT decreased progressively to normal limits within 12 months after the ischemic event, but aCL-IgM was still elevated (Fig. 2) . A resolution of infarct was illustrated 1 year later. He received regular checkups for conventional risk factor investigation annually but the results were all normal. Therefore, he is considered to be a case of subclinical antiphospholipid antibody syndrome or anticardiolipin antibody positivity without clinical symptoms. An increase of aCL-IgG is interpreted as the risk factor for his cerebral ischemia.
DISCUSSION
The increase of aCL-IgG in our patient may be argued for a result of acute inflammatory response or coincidence in normal population. Similar to some infections, aCL in these conditions is usually β 2 GPI-independent and therefore, is nonfunctional. We prefer an increase of aCL-IgG for his thrombotic calamity but not an accidental finding basing on: 1) aCL being β 2 GPI-dependent; 2) a concomitant prolongation of aPTT, indicating a functional activity of his aCL; 3) no subsequent change of aCL-IgM; 4) no surge of aCL afterward; and 5) a parallel recovery of aCL and aPTT during a follow-up period after a cessation of working. Clinically, a persistent increase of aCL-IgM would favor a case of antiphospholipid antibody syndrome (7) or antiphospholipid antibody positivity without clinical symptom. Nevertheless, an increase of aCL is never mentioned in relation to environmental chemical exposure although it has already been recognized an independent risk factor for cerebral ischemia (8) .
Furax process is a chemical reaction in that urea and formaldehyde are combined in a catalytic reactor into urea formaldehyde resin polymer under high temperature. Urea formaldehyde resin toxicity, such as contact dermatitis, urticaria, upper airway disorder or pulmonary disease, is occasionally reported in human. Right ventricle overload, left ventricle hypokinesia and increase of peripheral resistance are found in foundry workers exposure to urea formaldehyde resin (9) . Neurologic injury is uncommon. Rats receiving oral, inhalation, or dermal urea formaldehyde resin survive for 2 weeks without complication. However, our patient worked for more than 20 years continuously, and the chronic effect of repetitive exposures is unknown. Nevertheless, a decline of aCL-IgG after a cessation of his working supports an incidental association between his increased aCL-IgG and working environment. aCL-IgM (U/mL) aCL-IgG (GPL/mL) Formaldehyde, urea, intermediates, decomposed products, or other chemical constituents used or produced in the Furax process may display considerable adverse effect to our patient. Such as formaldehyde could induce an expression of intercellular adhesive molecule-1 and vascular cell adhesion molecule (10), inhibit endothelial proliferation (11) and subserve oxidative glycation and low-density-lipoprotein oxidation. In vivo, formaldehyde converted from adrenaline or methylamine in vascular smooth muscle cell causes stress-related angiopathy (12) , especially in diabetic patient. Although an associative relation between aCL and formaldehyde or other industrial chemicals has not been described, an abnormally high level of aCL could be induced by a number of drugs, especially procainamide and chloropromazine (13) . Interestingly, antinuclear antibody induced by these medicines are similar to formaldehyde. These evidences signify the diversity of the chemical effect on hemostasis and suggest a relationship among prothrombosis, autoimmunity, and environmental modulus.
Chloropromazine is known to induce antiphospholipid antibody by increasing the fluidity of membrane. Urea is a chaotropic solute to disrupt the homeoviscous adaptation on both protein and lipid structure, such as displaying a head group effect on membrane phospholipids. Formaldehyde, a genotoxic substance, causes a marked decrease in mitochondrial membrane potential, an inhibition of mitochondrial respiration, an increase of reactive oxygen species formation and a reduction of glutathione in a dosedependent manner in mammalian cells (14) . Therefore, both urea and formaldehyde are capable of affecting the bilayer lipid content, protein-lipid interaction, or mitochondrial structure. If so, an exposure of mitochondrial cardiolipin or β 2 GPI by formaldehyde or other chemicals may lead to an antigenic exposure or neoepitopic formation for subsequent antiphospholipid antibody formation in our patients.
Except for a decrease of natural killer cell response to α-interferon, immune indices do not change upon urea formaldehyde resin exposure ultimately (15) . On contrary, an exposure to formaldehyde causes an elevation of percent and absolute numbers of CD26 cells, autoantibodies, CD19 (B cells), and greater titers of isotypes of IgG and IgM to formaldehyde-human albumin serum, whereas a significant decrease of CD3 (total T cells), CD4 (T helper-inducer cells), and CD8 (T cytotoxic-suppressor cells) cell (16) . In experimental animals, Th1 suppresses while Th2 enhances the clinical features of antiphospholipid antibody syndrome (17) . In our patient, we do not find a significant alteration of the number of CD4 or CD8 cells similar to previous reports. Maybe an adaptation or tolerance develops already after repetitive exposures.
Several MHC class II loci are associated with aCL development in antiphospholipid antibody syndrome, including DR4, DR7, DR53, DQ7, C4 and especially DQB1 (18) . The TRAELDT residue is proposed the epitope and influences the immune response by affecting presentation of antigens to the T cell receptor. Linkage disequilibrium, ethnicity or environmental agent is able to affect the allelic expression. A modulation of autoimmune expression is not clear for urea formaldehyde resin, formaldehyde or other compounds. Bw44 increases the specific sensitization of chloropromazine to produce lupus anticoagulant (21). The presence of DR4 in our patient may trigger or enhance aCL response to chemical stimulation. The presence of aCL-IgM may reflect a continuum of humoral reaction to aCL-β 2 GPI, whereas the existence of aCL-IgG may implicate a polyclonal cell line.
CONCLUSION
In this patient, we expect to find that an activation of autoimmunity superimposed by a preexisting abnormal humoral reaction may be triggered by repetitive exposure to a selective chemical compound. This patient presents three points: 1) a chemical in the environment may trigger a pre-existing risk factor for stroke; 2) an environmental factor is always underestimated in stroke epidemiology; and 3) peculiar risk potential depends on the selective individual. A detailed investigation between environment and prothrombotic risk is warranted.
